Dyslipidemia and impaired glucose metabolism, are main health issues of growing 31 prevalence and significant high Health Care cost, requiring novel prevention and/or 32 therapeutic approaches. Epidemiological and animal studies revealed olive oil as an 33 important dietary constituent for normolipidemia. However, no studies have 34 specifically investigated the polyphenol rich water extract of olives (OLWPE), 35 generated during olive oil production. Here, we explore OLPWE in animals and human 36 metabolic parameters. High fat-fed rats developed a metabolic dysfunction, which 37 was significantly impaired when treated with OLWPE, with decreased LDL and insulin 38 levels and increased HDL. Moreover, they increased total plasma antioxidant capacity, 39 while several phenolic compounds were detected in their blood. These findings were 40 also verified in humans that consumed OLWPE daily for four weeks in a food matrix. 41 Our data clearly show that OLWPE can improve glucose and lipid profile, indicating its 42 possible use in the design of functional food and/or therapeutic interventions. 43 44
INTRODUCTION
Impaired glucose tolerance and lipid metabolism are the most common metabolic 46 dysfunctions in humans and they have been closely associated with obesity, now 47 recognized as a chronic disease of alarming incidence (close to 40% of adults in the 48 world are overweight or obese) 1 . Obesity complications can further result to a 49 number of life-threatening pathological conditions. In fact it is the various metabolic 50 disorders (such as dyslipidemia and impaired glucose tolerance) are usually seen in 51 central type obesity 2 together with increased blood pressure, that characterize a pro-52 inflammatory state 3,4 , leading to an increased likelihood of insulin resistance/type 2 53 diabetes, atherosclerosis/cardiovascular disease 5 . This, together with a resulting pre-54 thrombotic state 6 may result in premature death. This, obesity induced cascade of 55 events characterizes a pathophysiological state, commonly referred as "metabolic 56 inflammation". This is a low-grade inflammation triggered by adipose tissue 57 hypertrophy and hyperplasia and subsequent hypoxia. As a result, there is an altered 58 lipid metabolism and an increased production of several hormones, chemokines and 59 cytokines and coagulation factors that lead to hyperinsulinemia, β pancreatic cell 60 dysfunction, type II diabetes, increased sodium uptake, vasoconstriction and 61 hypertension, increased lipoprotein synthesis, gluconeogenesis and dyslipidemia, 62 endothelial dysfunction, atherosclerosis and clotting disorders and ultimately to 63 coronary heart disease. The collective cluster of (central) obesity, dyslipidemia, 64 impaired glucose tolerance/insulin resistance and hypertension is commonly refered 65 as the "metabolic syndrome" 7 66 Obesity, due to its high global prevalence and comorbidities, has become an 67 international health care priority, with the major aim being early diagnosis of 68 metabolic dysfunction and improvement of body weight and adverse metabolic 69 disturbances (mainly lipids and glucose) by dietary modifications and pharmaceutical 70 interventions. The cost of the latter is extremely high 8, 9 and therefore alternative 71 approaches, which may improve the above elements, are of great importance, both 72 for the health of the patients and for a possible reduction of the pharmaceutical 73 expenditure. 74 4 A great variety of animal and human epidemiological studies, report beneficial effects 75 of olive oil and / or olive -olive oil polyphenol extracts 10-12 on glucose and lipid 76 metabolism. However, during olive harvesting and olive oil production, a water phase 77 is also produced, commonly discarded. This phase is rich in olive (poly)phenols, which 78 distribute between the olive and water phase as a result of time of olive paste 79 malaxation and temperature. Here, we studied the effect of a microencapsulated 80 olives water phenolic extract (OLWPE) in a rat model of diet induced obesity and 81 extended our study (as a proof of principle) in a healthy human population that 82 consumed this extract in the context of a food matrix. Our findings clearly show that 83 OLWPE can ameliorate main metabolic parameters, such as fasting glucose levels and 84 lipid profile, indicating its possible dietary and/or therapeutic use. 
RESULTS

86
Polyphenolic characterization of OLWPE 87 The phenolic content of concentrated OLWPE was initially estimated as 10mg/ml 88 Trolox equivalents, while NMR analysis ( Figure 1A) , revealed that the extract, as 89 expected, contains phenolic compounds along with other larger amounts of small 90 molecular weight chemicals, such as ethanol, lactic, succinic and acetic acid and 91 carbohydrates. Analysis of the phenolic area of the spectrum revealed that the main 92 phenolic compound present is the phenylethanoid tyrosol, along with small amounts 93 of ligstroside and possibly elenolic acid, which is a common phenylethanoid hydrolysis 94 product. Further analysis of the extract by the more sensitive LC-ESI-MS/MS method 95 showed also the presence of the phenylethanoids oleuropein and verbascoside, the 96 flavanols catechol, catechin, and epicatechin, the flavones apigenin, apigenin-7-o-97 glucoside and luteolin, the flavonols quercetin and rutin and a number of phenolic 98 acids such as caffeic, ferrulic, gallic, 3-hydroxy-4-methoxy-cinamic, homovanillic, 99 hippuric, coumaric, siringic, p-hydroxy-benzoic acid, protocatechuic acid 100 (Supplemental Table 1 ).
101
The above extract was stabilized by micro-encapsulation and used in the subsequent 102 long-term metabolic studies, described below.
103
Animal study 104 OLWPE bioavailability and absence of toxicity in an animal model 105 Initially, in order to examine the bioavailability of the phenolic compounds in the 106 extract, rats were given a single dose (corresponding to the dose D3 of the long-term 107 study, see below and Material and Methods for further details) of OLWPE by gavage, 108 blood was withdrawn at different time points (1-24h) and serum was analyzed by LC-109 ESI-MS/MS. As soon as one hour after treatment, a number of phenolic compounds 110 have been detected in animal serum ( Figure 1B and C) including epicatechin, 111 quercetin, caffeic, gallic, coumaric, homovanillic, and p-hydroxy-benzoic acid. This 112 early appearance of phenolics in the blood suggests an early gastric absorption. For 113 6 caffeic, gallic, and coumaric acid, increased levels were also detected after 18 and/or 114 24h, indicating significant intestinal absorption, as well as, a possible increase as a 115 result of (poly)phenol metabolism. As expected, oleuropein, was not detected since, 116 due to its high molecular weight, it does not cross the intestinal barrier. Interestingly, 117 its primary metabolite, hydroxytyrosol, was also not equally detected. Comparing the 118 different AUC values, the compound with the greater bioavailability is ferrulic acid, 119 followed by p-hydroxy-benzoic and homovanillic acid. The latter being a metabolite of 120 hydroxytyrosol possibly explains its absence from the serum of treated animals. 121 Bioavailability data were also obtained during a long-term animal study, in which rats 122 were fed with three different doses (D1<D2<D3) of microencapsulated OLWPE 123 extract, for a period of 16 weeks. As shown in Figure 1D Figure 1E ). 133 Finally, at the end of the long-term animal study, rat livers and kidneys were examined 134 in order to rule out any signs of toxicity that could be attributed to the polyphenolic 135 extract. For this reason, organs were removed, formalin-fixed, paraffin embedded and 136 sectioned for haemotoxylin-eosin staining. In Figure 2 Effect of diets on rat weight 143 As it is shown in Figure 3A the final weight, as well as total weight gain, was elevated 144 in rats receiving HF food alone or in combination with any of the tested OLWPE doses 145 compared to the control rats. This indicates that HF diet induced obesity and OLWPE 146 did not have any effect on body weight per se. group. Additionally, insulin levels that were elevated in the HF only group compared 158 to the control group, were decreased back to normal levels in rats receiving all three 159 doses of the polyphenolic extract ( Figure 4C ). Finally, leptin that was significantly 160 increased in HF diet rats was not modified by OLWPE ( Figure 4D ). This finding is in 161 accordance with the lack of differences in the body weight between the HF only fed Human study 176 The above presented results from the animal study suggest that chronic consumption 177 of OLWPE polyphenols, can improve the lipid profile of animals and reduce glucose 178 levels and decrease insulin requirements. However, animal data are not easily 179 extrapolated in humans, due mainly to a significantly different metabolism between 180 the two species. Therefore, in order to explore whether the same effect can be 181 obtained in humans, we have performed a proof of concept study, by administering 182 microencapsulated OLWPE polyphenols (in a dose equivalent to the D2 dose used in 183 the animal study, as the total polyphenol content included in the daily dose of olive 184 oil approved by EFSA) in apparently healthy individuals. However, anthropometric 185 data (Supplemental Table 2 ) showed that 19 out of the 35 participants were 186 overweighted/obese (BMI >26) and 6 had a systolic blood pressure >130 mm Hg. The 187 baseline biochemical analysis of our group revealed that 14 individuals had a fasting 188 blood glucose >100 mg/dl, indicative of a pre-diabetic state, 26 presented a total 189 cholesterol >200 mg/dl, 21 presented LDL cholesterol >130 mg/dl and 6 presented 190 triglyceride levels >100 mg/dl. However, their HDL levels were astonishingly high 191 (mean±SD 66.4±10.7 mg/dl), compatible with a high consumption of vegetables and 192 olive oil, typical of a Cretan diet, followed by all participants.
147
OLWPE significantly lowers circulating lipids and insulin levels
193
NMR-based plasma metabolomics
194 At a first approach to identify changes in participants' metabolism, when OLWPE is 195 included in the diet of humans, serum samples from each participant before and after 196 a four week OLWPE consumption were analyzed by NMR. Figure 5A can be attributed to the dose administered that corresponds to dose 2 of the animal 226 model that equally has no significant effect on the different cell populations. 227 In all participants, no modification of circulating hepatic enzymes (SGOT, SGPT), urea 228 or creatinine levels was observed (not shown), ensuring that this product does not 229 10 express any hepatic or renal toxicity, at least for the period of its administration. 230 Furthermore, no significant modification of body weight was observed, as expected, 231 in the one-month interval of OLWPE consumption. can be found in blood 15 , and can interfere with major cellular processes having a 238 beneficial impact on cancer reviewed in 13 , vascular function 16,17 , and metabolism 18,19 . 239 The beneficial role of olive oil consumption is now-a-days widely recognized, with the 240 European Food Safety Authority (EFSA) approving two health claims regarding olive 241 oil 20 . They suggest its use to replace saturated fats in order to keep normal blood 242 cholesterol levels and protect blood lipids from oxidative stress with the later effect 243 to be achieved by olive oil polyphenols contained in a daily intake of 20 g of olive oil. 244 In numerous studies, diets enriched either in virgin olive oil or following the pattern Furthermore, a significant amelioration of specific metabolic parameters was 323 observed in those individuals identified with elevated cardio-metabolic risk factors (at 324 least 2 factors among fasting glucose and insulin, triglycerides, total and LDL 325 cholesterol, n=18). These findings are in accordance to previous studies that report a 326 beneficial effect of olive oil and its phenolic constituents on lipid profile 44-49 . 327 Moreover, oxidized LDL which is known to actively participate in atheromatous plaque 328 formation and atherosclerosis, was significantly decreased in OMWPE-treated 329 individuals, supporting the beneficial effect of OLWPE on cardiovascular risk factors. 330 Additionally, it is of great importance that with the inclusion of OLWPE in the diet 331 (both in animals and humans) a normal insulin sensitivity was restored. In fact, it is the 332 first study reporting a direct effect of olive water extract polyphenols on fasting 333 glucose and insulin levels, while all previous studies were conducted with olive oil see 334 for example 50, for a recent publication . Finally, eventhough overweighted/obese individuals 335 exhibited an increase in peripheral blood CD4 + CD25 + T regulatory cells (as also 336 observed in the animal model), OLWPE consumption had no effect mainly due to the 337 given dose which was also ineffective in animals. 338 Overall, we conclude that OLWPE can exhibit a beneficial health effect, mainly by 339 modifying circulating lipids and glucose/insulin levels, and most importantly without Folin-Ciocalteu method 55 that has been modified in order to use small volumes. 356 Briefly, 20 μl sample was mixed with 80 μl of distilled water, 400 μl Na 2 CO 3 (10% 357 Na 2 CO 3 in 0.85 N NaOH), and 500 μl Folin-Ciocalteu reagent (10%). The mixture was 358 allowed to stand for 1 hour in the dark and absorbance was measured at 750 nm. The Harlan Laboratories were used (n=4). In each animal, a single dose of the extract 393 (containing 3.42mg total polyphenols, corresponding to Dosage 3, see below) was 394 given by gavage, directly to the stomach and the animals were single caged, had 395 unlimited access to food and water and were kept under normal laboratory 396 conditions. They were closely monitored for 24h and blood sample was collected at Table 3 ). Animals were caged in groups of 3-4 rats, had unlimited access to food and water and 420 were kept under normal laboratory conditions. They were randomly assigned in 5 421 study groups (n=8 animals per group): 1) the Control group (normal diet), 2) the high 422 fat (HF) diet group, 3) the high fat + Dosage 1 (HF +D1) group, 4) the high fat + Dosage 423 2 (HF +D2) group and 5) the high fat + Dosage 3 (HF +D3) group. Rats were kept on 424 these diets for 4 months ad libitum. During this period, animals were closely 425 monitored, their weight was measured weekly. At the start and at the end of the 426 study, animals were fasted for 12-14h and afterwards blood samples were collected, 427 for complete blood cell counting, immunophenotyping and biochemical analysis. 428 When animals were sacrificed at the end of the study, selected tissues (kidney, liver, 429 lungs, fat and heart) were also kept for histological analysis. Table 4 ), baseline data collection, test phase I (4 weeks), washout period (2 weeks) and a test phase II (4 weeks). Participants were divided into two groups. Group A consumed the meat product containing the microencapsulated OLWPE in test phase I and the same meat product without the microencapsulated OLWPE in test phase II and group B in the reverse order. Blood sample collection and weight measurements were taken at the start of the study (baseline values, t=0) at the end of phase I (t=1) and at the end of phase II (t=2) All participants gave written informed consent to participate in the study. The study was approved by the Ethics Committee of the Heraklion University Hospital (Protocol no 10714) and was performed in accordance with relevant guidelines and regulations.
Diet
All participants in each test phase were on a free diet (a 3 day food record at t0, which represents the participants' usual diet before study, and at t1 and t2 was obtained. All participants adhered to Mediterranean diet as estimated by Mediterranean Diet Score lipoproteins. 59 Low MW metabolites were quantified in the CPMG NMR spectra using 508 the ChenomX suite (ChenomX, SA). Both CPMG and diffusion-edited LED spectra were 509 bucketed and the data were used directly for metabolomics analysis, which was 510 performed using the Simca 13.02 software package by Umetrics. 511 Complete blood cell count, the levels of different biochemical and metabolic 512 parameters (glucose, insulin, triglycerides, total cholesterol, LDL cholesterol, HDL 513 cholesterol, CRP, urea, creatinine, γGT, SGOT and SGPT) and Total Antioxidant 514 Capacity (TAC) were obtained as described above. 515 Immunophenotyping was performed as described above using the following anti- 
